Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 1.00 |
| ▸ | FAAH | O00519 | 14/20 | 1.00 |
| ▸ | AADAC | P22760 | 1/20 | 0.80 |
| ▸ | RAF1 | P04049 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256246 | 1.00 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL15612815 | 1.00 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL22223914 | 0.91 | EPHX2 (0.84) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL22223736 | 0.91 | EPHX2 (0.84) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL31114553 | 0.91 | EPHX2 (0.83) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL19358914 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL19358879 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL31114447 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL19358878 | 0.90 | EPHX2 (1.00) | EPHX2FAAHAADACRAF1 | |
| SCHEMBL17420136 | 0.89 | EPHX2 (0.83) | EPHX2FAAHAADACRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | claimed |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | claimed |
| CN-119528936-A | Ballon Sha Wei derivative and application thereof | 深圳安泰维生物医药有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-118557564-A | Application of 14, 15-epoxy eicosatrienoic acid in preparation of medicine for treating traumatic brain injury | 人工智能与数字经济广东省实验室(广州) | 2024-08-30 | — | — | CN | claimed |
| CN-117731650-A | Method for preventing and treating intestinal injury caused by high-sugar diet and application thereof | 重庆医科大学 | 2024-03-22 | — | — | CN | claimed |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-03-14 | — | — | US | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | claimed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | claimed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | claimed |
| CN-107132293-B | Novel method for rapidly detecting EETs of brain tissues | 南方医科大学 | 2020-12-15 | — | — | CN | claimed |
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | claimed |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | claimed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | claimed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | claimed |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-05 | — | — | US | claimed |
| EP-2846825-A1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | The Regents of The University of California (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2013138118-A1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | WO | claimed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | EPHX1, NCEH1, SOST | EPHX2 4/4885FAAH 61/4885AADAC 3264/4885 |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | EPHX1, ALDH1A2, EPHX2 | EPHX2 3/4885FAAH 30/4885AADAC 1919/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885FAAH 33/4885AADAC 717/4885 |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885FAAH 12/4885AADAC 2120/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885FAAH 13/4885AADAC 1463/4885 |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885AADAC 873/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX2 10/4885FAAH 213/4885AADAC 2390/4885 |
| US-11690837-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885AADAC 873/4885 |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | TNF, PTGES2, IL2 | EPHX2 13/4885FAAH 16/4885AADAC 1640/4885 |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | GLS, REN, SLC5A2 | EPHX2 3353/4885FAAH 4685/4885AADAC 4383/4885 |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885FAAH 1/4885AADAC 871/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | EPHX2 1139/4885FAAH 69/4885AADAC 747/4885 |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | EPHX1, SERPINB1, PTGES | EPHX2 13/4885FAAH 11/4885AADAC 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.